Holen Sie sich die Stockscreener-App
737.67
2.09%
15.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly Stock Faces Headwinds as CVS Caremark Favors Rival Wegovy for Weight-Loss Coverage | LLY Stock Price - paginasiete.bo
Pharmaceutical giant plans $5.9B Houston facility and more news to know - InnovationMap
Eli Lilly (LLY) Edges Higher in Early Trading: Key Metrics Investors Are Watching - Daily Chhattisgarh News
Lilly duets with 'Modern Family' star Eric Stonestreet for Mounjaro campaign - PR Week
Eli Lilly’s Strong Market Position and Innovative Drug Pipeline Justify Buy Rating with Target Price of USD 1,010 - TipRanks
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF. - The Motley Fool
Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On - TipRanks
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions - Eli Lilly and Company
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
UBS maintains Eli Lilly stock with $1,050 target - Investing.com
Novo Is Losing Steam. Can It Oh, Oh, Oh, Obtain New Grounding? - Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run - MarketBeat
Eli Lilly (LLY) Gains Upper Hand in Weight-Loss Drug Market | LL - GuruFocus
Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director - Health Tech World
The weight loss war: Who is winning out between Novo-Nordisk and Eli Lilly? - Shares Magazine
‘Start a Position’ in Eli Lilly Stock (LLY), Says Jim Cramer - TipRanks
Is Eli Lilly And Company Stock Underperforming The Dow? - Barchart.com
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - TradingView
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout - BioWorld MedTech
BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail
Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net
Lilly to acquire biotech developing pain drugs - statnews.com
Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal
Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers
Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey
Lilly snags Peninsula non-opioid pain drug company for up to $1 billionSan Francisco Business Times - The Business Journals
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives - Benzinga
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360
Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus
Lilly to buy pain drug developer SiteOne, challenging Vertex - BioPharma Dive
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters
Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks
Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus
Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus
Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news
Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com
Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company - Eli Lilly and Company
Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lilly's blood drive breaks site record - reporter.net
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - AOL.com
Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):